– FDA approval based on the phase 3 CABINET pivotal trial, which demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus placebo ...

Surufatinib did not provide an OS benefit over placebo, but there was a high rate of crossover from the placebo group to the surufatinib group.

According to Precedence Research, the radiopharmaceuticals market size has been estimated at USD 7.51 billion in 2025 and is projected to reach approximately USD 14.44 billion by 2034, growing at a ...

Sales rose 34% to $458 million in the first nine months of 2023 from its use as a second-line or later treatment for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs), a ...

Targeted radionuclide therapy, another type of systemic radiation therapy, can treat advanced prostate cancer or gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Sometimes your doctor can ...

The advent of targeted radiopharmaceuticals is revolutionising the field of oncology. These innovative therapies integrate systemically delivered radiotherapy into diagnostic and personalised ...

A total of 13 patients were enrolled: 10 patients with gastroenteropancreatic ... The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-a-NET) programs are in Phase 1/2a imaging and therapy ...

A total of 13 patients were enrolled: 10 patients with gastroenteropancreatic ... The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are in Phase 1/2a imaging and ...

A total of 13 patients were enrolled: 10 patients with gastroenteropancreatic-NETs (GEP-NETs ... The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs are in Phase 1/2a imaging ...

“The characteristics of NET vary widely from patient to patient, and very few treatment options have demonstrated the ability to improve outcomes across such a heterogeneous population,” said Jennifer ...